THE INVESTOR

메뉴열기
March 19, 2024

SillaJen plans clinical trials of JX-970 next year

PUBLISHED : January 22, 2018 - 16:23

UPDATED : January 22, 2018 - 16:26

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • sms

[THE INVESTOR] Korean pharmaceutical firm SillaJen said on Jan. 22 that it has signed a manufacturing agreement with France-based ABL Europe to help initiate early-stage studies of its oncolytic viral immunotherapy candidate JX-970 in 2019.

Under the deal, ABL -- a pharmaceutical contract manufacturing firm -- will produce JX-970 to be used in upcoming clinical trials. 




According to SillaJen, JX-970 is derived from the Western Reserve strain vaccinia virus and its tumor selectivity has been optimized by deleting thymidine kinse and the vaccinia growth factor. SillaJen plans to enter phase 1 clinical trials of JX-970 on patients with solid cancer in the first half of 2019.

“We may file Investigational New Drug applications in both the US and Europe this year, but the exact timeline and place are yet to be decided,” a SillaJen official told The Investor.

The latest contract reinforces the partnership between the two companies, which have been working together on SillaJen’s first cancer-fighting virus Pexa-Vec. The company’s lead drug candidate Pexa-Vec is under phase 3 clinical studies on patients with liver cancer.

By Park Han-na (hnpark@heraldcorp.com)

  • 페이스북
  • sms
최상단으로
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.